(Total Views: 224)
Posted On: 05/08/2019 2:54:34 PM
Post# of 154738
Thank you for the update and always providing an honest opinion that is backed up with data, facts, and/or personal action.
I haven't been lucky enough to get any orders filled sub-$.40, but have added some last week and yesterday in the low $.40s.
They still have some preferred shares they could issue, but let's hope they have something better in the works and avoid letting shares go at this price. Someone else has mentioned previously, but if they are going to issue more shares, I wish they would do an offering similar to what GALT did recently and do an offering to all current shareholders.
On the science front, preclinical data continues to impress. I recall them previously mentioning that they were going to try and save some of the control mice (maybe around the 6-8 week mark) and appears they were successful to a certain extent with 50% were still alive at 16 weeks (16 years in humans).....and metastasis was still undetectable after 9 weeks. Com'on Quest, inject and get the clinical cancer clock started!!
I haven't been lucky enough to get any orders filled sub-$.40, but have added some last week and yesterday in the low $.40s.
They still have some preferred shares they could issue, but let's hope they have something better in the works and avoid letting shares go at this price. Someone else has mentioned previously, but if they are going to issue more shares, I wish they would do an offering similar to what GALT did recently and do an offering to all current shareholders.
On the science front, preclinical data continues to impress. I recall them previously mentioning that they were going to try and save some of the control mice (maybe around the 6-8 week mark) and appears they were successful to a certain extent with 50% were still alive at 16 weeks (16 years in humans).....and metastasis was still undetectable after 9 weeks. Com'on Quest, inject and get the clinical cancer clock started!!
(0)
(0)
Please do your own due diligence. All my posts and comments are not to be considered investment advice.
